Blackstone Inc
ELVN icon

Blackstone Inc’s Enliven Therapeutics ELVN Stock Holding History

Blackstone Inc’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-954,946
Closed -$14.7M – 441
2025
Q4 		$14.7M Sell
954,946
-365,646
-28% -$7.28M 0.06% 86
2025
Q3 		$27M Hold
1,320,592
– – 0.11% 64
2025
Q2 		$26.5M Buy
1,320,592
+558,285
+73% +$10.6M 0.11% 59
2025
Q1 		$15M Buy
762,307
+388,984
+104% +$8.37M 0.06% 66
2024
Q4 		$8.4M Hold
373,323
– – 0.04% 80
2024
Q3 		$9.53M Buy
373,323
+52,143
+16% +$1.21M 0.04% 78
2024
Q2 		$7.51M Buy
321,180
+295,989
+1,175% +$6.23M 0.03% 84
2024
Q1 		$443K Buy
+25,191
New +$386K ﹤0.01% 154

Other funds holding ELVN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return